The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 09, 2013
Filed:
Nov. 30, 2007
David John King, Solana Beach, CA (US);
Alison Witte, Scotts Valley, CA (US);
Heidi N. Leblanc, Mountain View, CA (US);
Richard Theolis, Santa Cruz, CA (US);
Asna Masood, Saratoga, CA (US);
Mark Yamanaka, Pleasanton, CA (US);
Kyra D. Zens, San Mateo, CA (US);
Sarah R. Reed, Santa Cruz, CA (US);
Tim Sproul, Livermore, CA (US);
Chetana Rao-naik, Walnut Creek, CA (US);
David Passmore, Mountain View, CA (US);
Dawn M. Tanamachi, San Carlos, CA (US);
Kristopher Toy, San Jose, CA (US);
David John King, Solana Beach, CA (US);
Alison Witte, Scotts Valley, CA (US);
Heidi N. LeBlanc, Mountain View, CA (US);
Richard Theolis, Santa Cruz, CA (US);
Asna Masood, Saratoga, CA (US);
Mark Yamanaka, Pleasanton, CA (US);
Kyra D. Zens, San Mateo, CA (US);
Sarah R. Reed, Santa Cruz, CA (US);
Tim Sproul, Livermore, CA (US);
Chetana Rao-Naik, Walnut Creek, CA (US);
David Passmore, Mountain View, CA (US);
Dawn M. Tanamachi, San Carlos, CA (US);
Kristopher Toy, San Jose, CA (US);
Medarex, Inc., Princeton, NJ (US);
Abstract
The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.